How do you distinguish this entity from other plasma cell disorders (eg. MGUS, MM, etc.)?
Review of literature suggests that most of these patients have been treated with CVP or alkylators plus corticosteroids with poor results. Is there experience with newer agents or regimens utilized for myeloma?